Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of Cell and Gene Therapy (ISCT)’s annual meeting. The team briefed an expert cell therapy audience on two abstracts in a move Yatomi-Clarke believes exemplifies the Prescient pipeline’s utility and innovation. The CEO says there’s plenty of news to come in FY24 as Prescient readies CellPryme and OmniCAR for clinical studies.
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference
